Stereotaxis, Inc. (STXS)
NYSE American · Healthcare · Medical Instruments & Supplies
$1.180.00%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $118M
- 52-week range
- $1.17 – $3.59
- 52-week change
- −62.89%
- EPS (trailing)
- −$0.24
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Revenue
- $32.4M (+20.28%)
- Net income
- −$21.6M
- Operating margin
- −68.3%
- Diluted EPS
- −$0.25
- Free cash flow
- −$13.8M
From the company’s annual report on SEC EDGAR.
About Stereotaxis, Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices.
Headquarters: Saint Louis, United States · 131 employees · stereotaxis.com